Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron

Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples

Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled.

Investors Business Daily

Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin

Regeneron Pharmaceuticals said sales of its linchpin Eylea drug have been negatively impacted by a short-term shift to rival drug Avastin.

Investors Business Daily

Dexcom Leads 5 Stocks Near Buy Points

Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

What was the longest-running Covid infection and how were they cured?

A British man tested positive for Covid for more than two years and survived - but many more have Long Covid

Evening Standard

Regeneron, Bayer offer more promising data for aging eye drug

Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.

Tribune News Service

Top Funds Focus Their Cash On These Three Sectors

The best mutual funds are scooping up medical, financial and energy names. But they have their eyes on these other sectors.

Investors Business Daily

Regeneron Sinks Despite Massive Earnings Beat On A Notable Blockbuster Miss

Regeneron Pharma topped third-quarter expectations Thursday, reporting less of a decline than expected. But REGN stock was down early.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments.

Investors Business Daily

A Colorado teen’s long COVID isn’t just persisting — after 2 years, it’s getting worse

DENVER -- Reminders of life outside Lilly Downs’ Denver hospital room dotted the walls.

The Denver Post

Regeneron's Eylea Win Leaves an Elephant in the Room

Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.

The Street

Regeneron Stock Soars On Pair Of Successful Trials

Studies "support aflibercept 8 mg as a potential new standard-of-care," Regeneron Pharmaceuticals said. Regeneron stock leapt in huge volume.

Investors Business Daily

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Benzinga

Regeneron Soars As Eylea Outplays Competition, Both Beating Forecasts And Growing

Regeneron Pharmaceuticals outplayed its competition in eye diseases Wednesday, reporting Eylea sales that beat, leading REGN stock to soar.

Investors Business Daily

How Donald Trump’s fight with Covid unfolded two years before Biden diagnosis

Low blood oxygen levels and lung issues led officials to believe Trump might have to be put on ventilator in 2020

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Could The Next CRISPR From Verve, Beam Signal The End To High Cholesterol?

Verve Therapeutics said Tuesday it edited the genes of someone with high cholesterol. The first-ever move could push VERV stock higher.

Investors Business Daily

Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?

The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.

Benzinga

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Benzinga

U.S. FDA Accepts Regeneron's Diabetic Retinopathy Candidate Submission For Review

The U.S. Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ (NASDAQ: REGN) supplemental Biologics License Application (sBLA) of EYLEA (aflibercept) Injection for review in patients with diabetic retinopathy (DR).

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children

The U.S.

Investors Business Daily

Stock Market Near Session Lows; These Health Care Leaders Tumble

The stock market gave back most of its early gains and traded near session lows in afternoon trading. Amazon.com rose in the first day of its stock split.

Investors Business Daily

Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer

Regeneron stock tumbled Thursday after the company announced a deal to acquire the international rights to Sanofi-partnered cancer drug Libtayo.

Investors Business Daily

Oil Stocks Lead Charge Of Breakouts And Buy Zones In New Uptrend

With a new uptrend underway, oil stocks like TotalEnergies and tech stocks like Synopsys set the stage for new breakouts.

Benzinga

FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease

The U.S.

Benzinga

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

Investors Business Daily

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now

AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.